Ancora Biotech
Founders
Ben Buelow, MD, PhD - Co-Founder
Roland Buelow, Ph.D. - CEO
Wim Van Schooten - Co-Founder
Founded
2021
Stage
Series A
Invested
2022
Status
Acquired by AstraZeneca
Lightspeed Team
Dr. Galym Imanbayev - Partner
Jonathan MacQuitty - Partner
Christopher Schaepe - Partner

Developer of breakthrough biotherapeutics for B cell cancers, metabolic diseases, and chronic hepatitis B infections

Ben Buelow, MD, PhD (Co-founder), Roland Buelow, PhD (Co-founder), Wim Van Schooten, PhD (Co-founder)

Ancora Biotech
Fraction Fraction

Faction Ventures, LLC (“Faction”) and Lightspeed Management Company, L.L.C. (“Lightspeed”) are separate businesses that operate independently of each other. Faction is a registered investment adviser under the United States Investment Advisers Act of 1940, as amended. Faction advises its own fund(s) and does not advise any Lightspeed clients, and Lightspeed does not advise Faction or any of its clients. Lightspeed and Faction are parties to an agreement pursuant to which Lightspeed holds certain interests in Faction and the fund(s) Faction manages.

continue to the Faction Site